XyloCor hires Reinhardt as CMO to lead gene therapy programs

Reinhardt and XyloCor CEO Gianchetti both worked at GSK earlier in the decade. (Pixabay / rawpixel)

XyloCor Therapeutics has named Rickey Reinhardt as CMO. Reinhardt, who helped GlaxoSmithKline get a gene therapy to market, joins XyloCor to take genetic treatments for cardiovascular diseases through clinical development.  

Philadelphia-based XyloCor set itself up to move a gene therapy treatment for treatment-resistant angina into clinical development late last year when it raised $17 million in a series A co-led by LSP and Sofinnova Partners. The gene therapy, XC001, is designed to improve blood supply by stimulating the formation of coronary blood vessels.

Al Gianchetti, who spent more than 20 years at GSK across two stints, is leading XyloCor and has turned to one of his former colleagues for support. Gianchetti and Reinhardt crossed paths at GSK earlier in the decade. During that time, Reinhardt helped to get the ex-vivo gene therapy Strimvelis to market.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Reinhardt left GSK in 2016 to take up the position of VP, clinical R&D at Regenxbio. That position put Reinhardt in charge of translational medicine and clinical development for Regenxbio’s early phase gene therapy programs targeting rare neurodegenerative pediatric disorders and an eye indication.

After two years at Regenxbio, Reinhardt moved on, taking up the CMO role at Comet Therapeutics. Comet is working to treat inborn errors of metabolism.

XyloCor is betting that the experience Reinhardt gained at those companies will benefit its pipeline as it moves XC001 into phase 1 and progresses another cardiac candidate toward the clinic. 

“His proven success in driving drug development from discovery through phase 4 in areas such as oncology, cardiometabolics and rare diseases, including several clinical-stage gene therapy programs, will be a tremendous asset to our company,” Gianchetti said in a statement. 

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.